Nothing new discussed however they were still extremely confident of a positive CE Mark determination. While the Brexit machinations have no bearing on the Oncolsil certificate when issued, there was a sense that the overall workload imosed on BSI by Brexit has slowed down the Oncosil review. Also some good clarification on the resection rates/R0 rates compared to literature review which suggests that resection rate with same chemo drugs alone c15% vs. 24% combined with Oncosil. Directors expected 4-5 resections (10%) heading into the study. This bodes well for redesigning the pivotal study in the US to potential cover different endpoint(s) and reduce sample size
Nothing new discussed however they were still extremely...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $69.42K | 8.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 28673846 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 7597003 | 11 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |
